Perspectives in GLP-1 Research: New Targets, New Receptors

Trends in Endocrinology and Metabolism

Volumn 27, Issue 6, 2016, Pages 427-438

  Cantini, Giulia ^a   Mannucci, Edoardo ^a,b   Luconi, Michaela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cardioprotection; GLP 1 receptor agonists; Glucagon like peptide 1; Incretins

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INCRETIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADIPOSE TISSUE; BONE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HUMAN; LIVER; MUSCLE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; GENETICS; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HOMEOSTASIS; HUMANS; INCRETINS;

EID: 84963622915     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.03.017     Document Type: Review

References (86)

1. Baggio L.L., et al. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
2. Sandoval D.A., et al. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 2015, 295:513-548.
3. Orskov C., et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 1989, 264:12826-12829.
4. Deacon C.F., et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80:952-957.
5. Kieffer T.J., et al. Degradation of glucose dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
6. Tudurí E., et al. Glucagon-like peptide 1 analogs and their effects on pancreatic islets. Trends Endocrinol. Metab. 2016, 27:304-318.
7. Madsbad S. A review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes. Metab. 2016, 18:317-332.
8. Franklin I., et al. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 2005, 54:1808-1815.
9. Richards P., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014, 63:1224-1233.
10. Noyan-Ashraf M.H., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
11. Younce C.W., et al. Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am. J. Physiol. Cell. Physiol. 2013, 304:C508-C518.
12. Sonne D.P., et al. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 2008, 146:243-249.
13. Mannucci E., et al. Incretin-based therapies and cardiovascular risk. Curr. Med. Res. Opin. 2012, 28:715-721.
14. White W.B., et al. Cardiovascular effects of incretin-based therapies. Annu. Rev. Med. 2016, 67:245-260.
15. Bernink F.J., et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. Int. J. Cardiol. 2013, 167:289-290.
16. Lønborg J., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 2012, 33:1491-1499.
17. Pfeffer M.A., et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 2015, 373:2247-2257.
18. Schisano B., et al. GLP-1 analogue, liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul. Pept. 2012, 174:46-52.
19. Wang D., et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 2013, 62:1697-1708.
20. Wang R., et al. Effect of glucagon-like peptide-1 on high-glucose-induced oxidative stress and cell apoptosis in human endothelial cells and its underlying mechanism. Cardiovasc. Pharmacol. 2015, 66:135-140.
21. Ceriello A., et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013, 36:2346-2350.
22. Koska J., et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015, 64:2624-2635.
23. Chai W., et al. Glucagon-like peptide recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012, 61:888-896.
24. Wei Y., et al. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995, 358:219-224.
25. Hunter K., et al. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13:33.
26. Vrang N., et al. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog. Neurobiol. 2010, 92:442-462.
27. Baggio L.L., et al. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J. Clin. Invest. 2014, 124:4223-4226.
28. Larsen P.J., et al. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
29. Gao Y., et al. Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia 2014, 62:17-25.
30. Harkavyi A., et al. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br. J. Pharmacol. 2010, 159:495-501.
31. Mossello E., et al. Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. Exp. Diabetes Res. 2011, 2011:281674.
32. Monami M., et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp. Diabetes Res. 2012, 2012:672658.
33. Kanoski S.E., et al. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-3112.
34. Sisley S., et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Invest. 2014, 124:2456-2463.
35. D'Alessio D., et al. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm. Metab. Res. 2004, 36:837-841.
36. Valverde I., et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 1994, 349:313-316.
37. Redondo A., et al. Cell signalling of the GLP-1 action in rat liver. Mol. Cell. Endocrinol. 2003, 204:43-50.
38. Ikezawa Y., et al. Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically. Regul. Pept. 2003, 111:207-210.
39. Wang C., et al. GLP-1 contributes to increases in PGC-1α expression by downregulating miR-23a to reduce apoptosis. Biochem. Biophys. Res. Commun. 2015, 466:33-39.
40. Ding X., et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43:173-181.
41. Villanueva-Peñacarrillo M.L., et al. Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. Regul. Pept. 2011, 168:39-44.
42. Shi L., et al. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3 K/Akt signaling pathways. Cardiovasc. Diabetol. 2015, 14:18.
43. Nagayama K., et al. Exendin-4 prevents vascular smooth muscle cell proliferation and migration by angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways. PLoS ONE 2015, 10:e0137960.
44. Torres G., et al. Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation. Biochem. Pharmacol. 2016, 104:52-61.
45. Campbell J.E., et al. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013, 17:819-837.
46. Henriksen D.B., et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009, 45:833-842.
47. Meier C., et al. Effects of diabetes drugs on the skeleton. Bone 2016, 82:93-100.
48. Dicembrini I., et al. Bone: incretin hormones perceiver or receiver?. Exp. Diabetes Res. 2012, 2012:519784.
49. Mabilleau G., et al. Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J. Endocrinol. 2013, 219:59-68.
50. Jeon Y.K., et al. Expression of glucagon-like peptide 1 receptor during osteogenic differentiation of adipose-derived stem cells. Endocrinol. Metab. (Seoul) 2014, 29:567-573.
51. Lee H.M., et al. Effect of glucagon-like peptide-1 on the differentiation of adipose-derived stem cells into osteoblasts and adipocytes. J. Menopausal Med. 2015, 21:93-103.
52. Monami M., et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011, 34:2474-2476.
53. Mosenzon O., et al. Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care 2015, 38:2142-2150.
54. Bunck M.C., et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes. Metab. 2011, 213:374-377.
55. Mannucci E., et al. Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clin. Cases Miner. Bone Metab. 2015, 12:130-134.
56. Pi-Sunyer X., et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015, 373:11-22.
57. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012, 8:728-742.
58. Gao H., et al. GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 2007, 32:90-95.
59. Sancho V., et al. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J. Mol. Endocrinol. 2005, 35:27-38.
60. Challa T.D., et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J. Biol. Chem. 2012, 287:6421-6430.
61. Yang J., et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int. J. Mol. Med. 2013, 31:1429-1435.
62. Kim Chung le T., et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem. Biophys. Res. Commun. 2009, 390:613-618.
63. Shiraishi D., et al. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem. Biophys. Res. Commun. 2012, 425:304-308.
64. Cantini G., et al. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol. Cell. Endocrinol. 2007, 402:43-50.
65. Ban K., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
66. Ban K., et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
67. Kim M., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 2013, 19:567-575.
68. Ussher J.R., et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol. Metab. 2014, 3:507-517.
69. Pyke C., et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155:1280-1290.
70. Tomas E., et al. Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol. Metab. 2010, 21:59-67.
71. Nishimura E., et al. Regulation of glucagon receptor expression. Acta Physiol. Scand. 1996, 157:329-332.
72. Luque M.A., et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J. Endocrinol. 2002, 173:465-473.
73. Nuche-Berenguer B., et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J. Cell. Physiol. 2010, 225:585-592.
74. Montrose-Rafizadeh C., et al. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J. Cell Physiol. 1997, 172:275-283.
75. El-Ouaghlidi A., et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J. Clin. Endocrinol. Metab. 2007, 92:4165-4171.
76. Elahi D., et al. Does GLP-1 suppress its own basal secretion?. Endocr. Res. 2016, 41:16-20.
77. Grigoryan M., et al. Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology 2012, 153:3076-3088.
78. Yoder S.M., et al. Stimulation of incretin secretion by dietary lipid: is it dose dependent?. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G299-G305.
79. Drucker D.J., et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
80. Vahl T.P., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
81. Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br. J. Pharmacol. 2012, 166:27-41.
82. Thompson A., et al. The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression. Sci. Rep. 2014, 4:7410.
83. Huang Y., et al. Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br. J. Pharmacol. 2010, 159:237-251.
84. Runge S., et al. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 2008, 283:11340-11347.
85. Whitaker G.M., et al. Regulation of GIP and GLP-1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS ONE 2012, 7:e32675.
86. Chen Q., et al. Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E62-E68.